<?xml version="1.0" ?>
<!DOCTYPE pmc-articleset PUBLIC "-//NLM//DTD ARTICLE SET 2.0//EN" "https://dtd.nlm.nih.gov/ncbi/pmc/articleset/nlm-articleset-2.0.dtd">
<pmc-articleset><article xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" article-type="case-report">
  <?properties open_access?>
  <front>
    <journal-meta>
      <journal-id journal-id-type="nlm-ta">An Bras Dermatol</journal-id>
      <journal-id journal-id-type="iso-abbrev">An Bras Dermatol</journal-id>
      <journal-id journal-id-type="publisher-id">An Bras Dermatol</journal-id>
      <journal-title-group>
        <journal-title>Anais Brasileiros de Dermatologia</journal-title>
      </journal-title-group>
      <issn pub-type="ppub">0365-0596</issn>
      <issn pub-type="epub">1806-4841</issn>
      <publisher>
        <publisher-name>Sociedade Brasileira de Dermatologia</publisher-name>
      </publisher>
    </journal-meta>
    <article-meta>
      <article-id pub-id-type="pmid">24626663</article-id>
      <article-id pub-id-type="pmc">3938369</article-id>
      <article-id pub-id-type="doi">10.1590/abd1806-4841.20142887</article-id>
      <article-categories>
        <subj-group subj-group-type="heading">
          <subject>Case Report</subject>
        </subj-group>
      </article-categories>
      <title-group>
        <article-title>Segmental vitiligo after infliximab use for rheumatoid arthritis - A case
report<xref ref-type="fn" rid="fn01">*</xref>
</article-title>
      </title-group>
      <contrib-group>
        <contrib contrib-type="author">
          <name>
            <surname>Carvalho</surname>
            <given-names>Clarissa Luiza Dalla Bernardina</given-names>
          </name>
          <xref ref-type="aff" rid="aff01">1</xref>
          <xref ref-type="corresp" rid="c01"/>
        </contrib>
        <contrib contrib-type="author">
          <name>
            <surname>Ortigosa</surname>
            <given-names>Luciena Cegatto Martins</given-names>
          </name>
          <xref ref-type="aff" rid="aff02">2</xref>
        </contrib>
      </contrib-group>
      <aff id="aff01"><label>1</label> MD, resident in Dermatology at Hospital Regional de Presidente Prudente
- Universidade do Oeste Paulista (HRPP- UNOESTE) - Presidente Prudente (SP), Brazil. </aff>
      <aff id="aff02"><label>2</label> MD, Master's degree - Presidente Prudente (SP), Brazil. </aff>
      <author-notes>
        <corresp id="c01">MAILING ADDRESS: Clarissa Luiza Dalla Bernardina Carvalho, Rua Jos&#xE9;
Bongiovani, 1297, Vila Liberdade, 19050-680 Presidente Prudente, SP. E-mail:
<email>clarissadbernardina@hotmail.com</email></corresp>
      </author-notes>
      <pub-date pub-type="ppub">
        <season>Jan-Feb</season>
        <year>2014</year>
      </pub-date>
      <volume>89</volume>
      <issue>1</issue>
      <fpage>154</fpage>
      <lpage>156</lpage>
      <history>
        <date date-type="received">
          <day>20</day>
          <month>6</month>
          <year>2013</year>
        </date>
        <date date-type="accepted">
          <day>16</day>
          <month>7</month>
          <year>2013</year>
        </date>
      </history>
      <permissions>
        <copyright-statement>&#xAE;2013 by Anais Brasileiros de Dermatologia</copyright-statement>
        <license license-type="open-access" xlink:href="http://creativecommons.org/licenses/by-nc/3.0/">
          <license-p>This is an Open Access article distributed under the terms of the Creative
Commons Attribution Non-Commercial License which permits unrestricted
non-commercial use, distribution, and reproduction in any medium, provided the
original work is properly cited. </license-p>
        </license>
      </permissions>
      <abstract>
        <p>The tumor necrosis factor alpha is a cytokine related to immune and inflammatory
processes by acting on different parts of the body. It is secreted by several cell
types including macrophages, lymphocytes, monocytes, neutrophils, dendritic cells,
among others. Infliximab is a chimeric monoclonal antibody that specifically binds to
soluble and transmembrane tumor necrosis factor alpha form blocking its action. In
rheumatoid arthritis it is used because the cytokines that cause inflammation in this
disease are regulated by tumor necrosis factor alpha and IL-1. We report the case of
a 46-year-old patient with rheumatoid arthritis who developed segmental vitiligo
after two months using infliximab. The event aims to alert to the existence of this
adverse effect that can be induced with the use of this medication.</p>
      </abstract>
      <kwd-group>
        <kwd>Arthritis, rheumatoid</kwd>
        <kwd>Tumor necrosis factor-alpha</kwd>
        <kwd>Vitiligo</kwd>
      </kwd-group>
    </article-meta>
  </front>
  <body>
    <sec>
      <title>INTRODUCTION</title>
      <p>Rheumatoid arthritis (RA) is an autoimmune disease of unknown etiology, which affects
the synovial membranes and is characterized by peripheral symmetrical polyarthritis,
leading to deformity and destruction of joints by bone and cartilage erosion.<sup><xref rid="r01" ref-type="bibr">1</xref></sup>
</p>
      <p>After the discovery that on the synovial membrane of patients with RA occurs the
expression of several cytokines implicated in inflammatory reactions, the TNF&#x3B1; became
the ideal target for joint inflammation control. Infliximab is a chimeric monoclonal
antibody anti-TNF&#x3B1; of chimeric profile, that is, 75% human and 25% murine, which confers
to it greater specificity, affinity and high avidity due to both soluble and
transmembrane forms of TNF&#x3B1;.<sup><xref rid="r02" ref-type="bibr">2</xref></sup>
</p>
      <p>Several adverse effects have already been observed with the use of infliximab. The main
ones include allergic complications during or after the infusion, infections, autoimmune
events and lymphoproliferative diseases.<sup><xref rid="r03" ref-type="bibr">3</xref></sup>
</p>
      <p>Among the autoimmune complications, central nervous system demyelinating syndromes,
diabetes mellitus type 1, psoriasis, lupus-like cases and even systemic lupus
erythematosus, including laboratory alterations like ANF increase and development of
other autoantibodies.<sup><xref rid="r03" ref-type="bibr">3</xref>,<xref rid="r04" ref-type="bibr">4</xref>,<xref rid="r05" ref-type="bibr">5</xref>,<xref rid="r06" ref-type="bibr">6</xref></sup>
</p>
      <p>Vitiligo is a cutaneous disease, characterized by the presence of achromic macules of
different sizes and forms with the tendency of increasing centrifugally.<sup><xref rid="r07" ref-type="bibr">7</xref>,<xref rid="r08" ref-type="bibr">8</xref></sup>
</p>
      <p>Its etiopathogeny is related to autoimmunity, with occurrence of association with
thyroiditis, diabetes mellitus, alopecia areata and with HLA DR4, DW7, DR1, B13, A2,
B21, CW6, DR53, A19 and DR52. It can be classified as localized or generalized, the
localized form being divided into focal, when in a determined area without specific
distribution, and segmental when it involves a unilateral segment of the body following
a dermatome.<sup><xref rid="r07" ref-type="bibr">7</xref></sup>
</p>
      <p>Several cutaneous diseases have already been described with the use of immunobiologic
drugs, such as psoriasis, lichenoid eruptions, herpes zoster, vasculitis, alopecias and
cutaneous lymphomas;<sup><xref rid="r05" ref-type="bibr">5</xref></sup> however, the
relation between vitiligo and the use of anti-TNF&#x3B1; is rare and few cases have been
described, all of them associated with the use of infliximab. It is demonstrated for the
first time, in the segmental form and nationwide, in this report.<sup><xref rid="r03" ref-type="bibr">3</xref>,<xref rid="r04" ref-type="bibr">4</xref>,<xref rid="r05" ref-type="bibr">5</xref>,<xref rid="r06" ref-type="bibr">6</xref>,<xref rid="r09" ref-type="bibr">9</xref></sup>
</p>
    </sec>
    <sec>
      <title>CASE REPORT</title>
      <p>A forty-six-year old female patient, of mixed race, diabetic, with rheumatoid arthritis
for seven years. Denies personal or familial history of vitiligo. She mentioned the
onset of achromic macules six months ago, initially on the left hand, which progressed
in the craniocaudal direction involving all the left hemithorax and upper left limb.</p>
      <p>She was using infliximab every eight weeks for eight months.</p>
      <p>She was also using propranolol 20mg/day, metformin 850mg/day and glibenclamide
5mg/day.</p>
      <p>For this cutaneous state she had used topical 10% phenylalanine, clobetasol 0.025%, 2%
vitamin E and <italic>Polipodium leucotomos</italic> 240 mg/day orally for 30 days, at
another service, with no improvement.</p>
      <p>At the dermatological examination achromic macules were observed on the left upper limb
and left hemithorax, which under Wood's light presented nacreous white coloration (<xref ref-type="fig" rid="f01">Figure 1</xref>).</p>
      <fig id="f01" orientation="portrait" position="float">
        <label>FIGURE 1</label>
        <caption>
          <p>
<bold>A -</bold> Pre-treatment vitiligo on left hemibody; <bold>B -</bold>
Pre-treatment vitiligo on left hemibody</p>
        </caption>
        <graphic xlink:href="abd-89-01-0154-g01"/>
      </fig>
      <p>There were no abnormalities detected in the remainder of the physical exam.</p>
      <p>Among the laboratory exams she presented hemogram, biochemistry and thyroid hormones
without changes, serologies for HIV, hepatitis and syphilis negative and one ANF 1: 640
of mixed pattern, nuclear dense fine speckled and cytoplasmic dotted reticular, with
native anti-DNA autoantibodies, anti Jo, anticardiolipin, anti-centromere, anti Sm, anti
Ro, anti La, anti TPO negative.</p>
    </sec>
    <sec sec-type="discussion">
      <title>DISCUSSION</title>
      <p>The use of TNF&#x3B1; inhibiting agents has already been associated with cutaneous and also
autoimmune manifestations several times, from laboratory alterations of asymptomatic
nature to the presence of systemic diseases, including findings of autoantibodies like
ANF and anti-DNA.<sup><xref rid="r03" ref-type="bibr">3</xref>,<xref rid="r04" ref-type="bibr">4</xref>,<xref rid="r05" ref-type="bibr">5</xref>,<xref rid="r06" ref-type="bibr">6</xref></sup>
</p>
      <p>Among the hypotheses raised to explain the positivity of AFN with the usage of
infliximab is the induction of TNF&#x3B1;-producing cells lysis, exposing intracellular
particles to the immunesystem and leading to increase of this factor.<sup><xref rid="r03" ref-type="bibr">3</xref>,<xref rid="r06" ref-type="bibr">6</xref></sup>
</p>
      <p>The presence of autoantibodies against melanocytes in the bloodstream of patients with
vitiligo raises the theory of autoimmunity as its cause, and the presence of these
autoantibodies seems to be related to the extent of the disease in affected
patients.<sup><xref rid="r08" ref-type="bibr">8</xref></sup>
</p>
      <p>The skin damaged by vitiligo presents enhanced expression of TNF&#x3B1; and IL6 when compared
to perilesional skin; TNF&#x3B1; blocks the differentiation of melanocytic stem cells and can
induce the apoptosis of melanocytes which suggests that the blockage of these cytokines
might be the key to its treatment. However, to the contrary of what was suggested, the
case in question progressed with the onset of vitiligo.<sup><xref rid="r10" ref-type="bibr">10</xref></sup>
</p>
      <p>Vitiligo is an autoimmune disease, therefore the development of this infirmity
associated with the use of infliximab can be explained by the same lupus-like syndrome
mechanism.<sup><xref rid="r03" ref-type="bibr">3</xref></sup>
</p>
      <p>After searching databases, few cases were found reporting infliximab use as triggering
vitiligo; this was the first with progression to segmental form and also the first
nationwide.</p>
      <p>The patient here reported had never presented cutaneous lesions that would suggest
vitiligo and also denies familial history, developing the lesion after two months using
the drug, besides the ANF positivity.</p>
      <p>Since there was marked improvement of the articular clinical picture, we opted for
non-interruption of the drug and treatment of vitiligo with 8-methoxypsoralen 0.001% in
topical hydroalcoholic solution, followed by solar exposure and dexamethasone cream on
the macules at night (<xref ref-type="fig" rid="f02">Figure 2</xref>).</p>
      <fig id="f02" orientation="portrait" position="float">
        <label>FIGURE 2 </label>
        <caption>
          <p>
<bold>A -</bold> Vitiligo on left hemibody during treatment; <bold>B -</bold>
Vitiligo on left hemibody during treatment</p>
        </caption>
        <graphic xlink:href="abd-89-01-0154-g02"/>
      </fig>
      <p>Infliximab is as important for dermatology as it is for rheumatology and
gastroenterology, enhancing the quality of life of patients under treatment. However, we
should be always alert, not only to systemic collateral effects, but also to possible
cutaneous adverse effects associated with its use which will be more and more
evident.</p>
    </sec>
  </body>
  <back>
    <fn-group>
      <fn id="fn01" fn-type="other">
        <label>*</label>
        <p> Work performed at Hospital Regional de Presidente Prudente - Universidade do Oeste
Paulista (HRPP- UNOESTE) - Presidente Prudente (SP), Brazil.</p>
      </fn>
      <fn fn-type="financial-disclosure">
        <p>Financial funding: None</p>
      </fn>
      <fn fn-type="conflict">
        <p>Conflict of interest: None</p>
      </fn>
    </fn-group>
    <ref-list>
      <title>REFERENCES</title>
      <ref id="r01">
        <label>1</label>
        <element-citation publication-type="journal">
          <person-group person-group-type="author">
            <name>
              <surname>Mota</surname>
              <given-names>LMH</given-names>
            </name>
            <name>
              <surname>Laurindo</surname>
              <given-names>IMM</given-names>
            </name>
            <name>
              <surname>Neto</surname>
              <given-names>LLS</given-names>
            </name>
          </person-group>
          <article-title xml:lang="pt">Artrite Reumat&#xF3;ide Inicial - Conceitos</article-title>
          <source>Rev Assoc Med Bras</source>
          <year>2010</year>
          <volume>56</volume>
          <fpage>227</fpage>
          <lpage>229</lpage>
          <pub-id pub-id-type="pmid">20499000</pub-id>
        </element-citation>
      </ref>
      <ref id="r02">
        <label>2</label>
        <element-citation publication-type="journal">
          <person-group person-group-type="author">
            <name>
              <surname>Silva</surname>
              <given-names>LC</given-names>
            </name>
            <name>
              <surname>Ortigosa</surname>
              <given-names>LC</given-names>
            </name>
            <name>
              <surname>Benard</surname>
              <given-names>G</given-names>
            </name>
          </person-group>
          <article-title>Anti-TNF agents in the treatment of immuneme-diated inflammatory
diseases: mechanisms of actions and pitfalls. Immunotherapy</article-title>
          <source>Immunotherapy</source>
          <year>2010</year>
          <volume>2</volume>
          <fpage>817</fpage>
          <lpage>833</lpage>
          <pub-id pub-id-type="pmid">21091114</pub-id>
        </element-citation>
      </ref>
      <ref id="r03">
        <label>3</label>
        <element-citation publication-type="journal">
          <person-group person-group-type="author">
            <name>
              <surname>Ram&#xED;rez-Hern&#xE1;ndez</surname>
              <given-names>M</given-names>
            </name>
            <name>
              <surname>Marras</surname>
              <given-names>C</given-names>
            </name>
            <name>
              <surname>Mart&#xED;nez-Escribano</surname>
              <given-names>JA</given-names>
            </name>
          </person-group>
          <article-title>Infliximab-Induced Vitiligo</article-title>
          <source>Dermatology</source>
          <year>2005</year>
          <volume>210</volume>
          <fpage>79</fpage>
          <lpage>80</lpage>
          <pub-id pub-id-type="pmid">15604556</pub-id>
        </element-citation>
      </ref>
      <ref id="r04">
        <label>4</label>
        <element-citation publication-type="journal">
          <person-group person-group-type="author">
            <name>
              <surname>Lahita</surname>
              <given-names>RG</given-names>
            </name>
            <name>
              <surname>Vernace</surname>
              <given-names>MA</given-names>
            </name>
          </person-group>
          <article-title>Vasculitis, Vitiligo, Thyroiditis, and Altered Hormone Levels After
Anti-Tumor Necrosis Factor Therapy</article-title>
          <source>J Rheumatol</source>
          <month>3</month>
          <year>2011</year>
          <volume>38</volume>
          <issue>3</issue>
          <fpage>579</fpage>
          <lpage>580</lpage>
          <pub-id pub-id-type="pmid">21362795</pub-id>
        </element-citation>
      </ref>
      <ref id="r05">
        <label>5</label>
        <element-citation publication-type="journal">
          <person-group person-group-type="author">
            <name>
              <surname>Hern&#xE1;ndez</surname>
              <given-names>MV</given-names>
            </name>
            <name>
              <surname>Meineri</surname>
              <given-names>M</given-names>
            </name>
            <name>
              <surname>Sanmart&#xED;</surname>
              <given-names>R</given-names>
            </name>
          </person-group>
          <article-title>Skin Lesions and Treatment With Tumor Necrosis Factor Alpha
Antagonists</article-title>
          <source>Reumatol Clin</source>
          <year>2013</year>
          <volume>9</volume>
          <fpage>53</fpage>
          <lpage>61</lpage>
          <pub-id pub-id-type="pmid">22766431</pub-id>
        </element-citation>
      </ref>
      <ref id="r06">
        <label>6</label>
        <element-citation publication-type="journal">
          <person-group person-group-type="author">
            <name>
              <surname>Duarte</surname>
              <given-names>AA</given-names>
            </name>
            <name>
              <surname>Chehin</surname>
              <given-names>FB</given-names>
            </name>
          </person-group>
          <article-title>Moderate to severe psoriasis treated with infliximab - 53 patients:
patients profile, efficacy and adverse effects</article-title>
          <source>An Bras Dermatol</source>
          <year>2011</year>
          <volume>86</volume>
          <fpage>257</fpage>
          <lpage>263</lpage>
          <pub-id pub-id-type="pmid">21603808</pub-id>
        </element-citation>
      </ref>
      <ref id="r07">
        <label>7</label>
        <element-citation publication-type="journal">
          <person-group person-group-type="author">
            <name>
              <surname>Steiner</surname>
              <given-names>D</given-names>
            </name>
            <name>
              <surname>Bedin</surname>
              <given-names>V</given-names>
            </name>
            <name>
              <surname>Moraes</surname>
              <given-names>MB</given-names>
            </name>
            <name>
              <surname>Villas</surname>
              <given-names>RT</given-names>
            </name>
            <name>
              <surname>Steiner</surname>
              <given-names>T</given-names>
            </name>
          </person-group>
          <article-title>Vitiligo</article-title>
          <source>An Bras Dermatol</source>
          <year>2004</year>
          <volume>79</volume>
          <fpage>335</fpage>
          <lpage>351</lpage>
        </element-citation>
      </ref>
      <ref id="r08">
        <label>8</label>
        <element-citation publication-type="journal">
          <person-group person-group-type="author">
            <name>
              <surname>Correa</surname>
              <given-names>MCT</given-names>
            </name>
            <name>
              <surname>Vargas</surname>
              <given-names>LMG</given-names>
            </name>
          </person-group>
          <article-title>Vitiligo</article-title>
          <source>Rev Asoc Col Dermatol</source>
          <year>2009</year>
          <volume>17</volume>
          <fpage>76</fpage>
          <lpage>86</lpage>
        </element-citation>
      </ref>
      <ref id="r09">
        <label>9</label>
        <element-citation publication-type="journal">
          <person-group person-group-type="author">
            <name>
              <surname>Bonnet</surname>
              <given-names>N</given-names>
            </name>
            <name>
              <surname>Guis</surname>
              <given-names>S</given-names>
            </name>
            <name>
              <surname>Koeppel</surname>
              <given-names>MC</given-names>
            </name>
            <name>
              <surname>Roudier</surname>
              <given-names>J</given-names>
            </name>
            <name>
              <surname>Grimaud</surname>
              <given-names>JC</given-names>
            </name>
            <name>
              <surname>Jean-Pastor</surname>
              <given-names>MJ</given-names>
            </name>
            <etal>et al</etal>
          </person-group>
          <article-title>Cutaneous events during anti-TNF alpha therapy: a prospective
observational study of 41 cases</article-title>
          <source>Ann Dermatol Venereol</source>
          <year>2010</year>
          <volume>137</volume>
          <fpage>12</fpage>
          <lpage>20</lpage>
          <pub-id pub-id-type="pmid">20110063</pub-id>
        </element-citation>
      </ref>
      <ref id="r10">
        <label>10</label>
        <element-citation publication-type="journal">
          <person-group person-group-type="author">
            <name>
              <surname>Alghamdi</surname>
              <given-names>KM</given-names>
            </name>
            <name>
              <surname>Khurrum</surname>
              <given-names>H</given-names>
            </name>
            <name>
              <surname>Rikabi</surname>
              <given-names>A</given-names>
            </name>
          </person-group>
          <article-title>Worsening of vitiligo and onset of new psoriasiform dermatitis
following treatment with infliximab</article-title>
          <source>J Cutan Med Surg</source>
          <year>2011</year>
          <volume>15</volume>
          <fpage>280</fpage>
          <lpage>284</lpage>
          <pub-id pub-id-type="pmid">21962188</pub-id>
        </element-citation>
      </ref>
      <ref id="r11">
        <label>11</label>
        <element-citation publication-type="journal">
          <person-group person-group-type="author">
            <name>
              <surname>Machado-Filho</surname>
              <given-names>CDS</given-names>
            </name>
            <name>
              <surname>Almeida</surname>
              <given-names>FA</given-names>
            </name>
            <name>
              <surname>Proto</surname>
              <given-names>RS</given-names>
            </name>
            <name>
              <surname>Landman</surname>
              <given-names>G</given-names>
            </name>
          </person-group>
          <article-title>Vitiligo: analysis of grafting versus curettage alone, using
melanocyte morphology and reverse transcriptase polymerase chain reaction for
tyrosinase mRNA</article-title>
          <source>Sao Paulo Med J</source>
          <year>2005</year>
          <volume>123</volume>
          <fpage>187</fpage>
          <lpage>191</lpage>
          <pub-id pub-id-type="pmid">16389417</pub-id>
        </element-citation>
      </ref>
      <ref id="r12">
        <label>12</label>
        <element-citation publication-type="journal">
          <person-group person-group-type="author">
            <name>
              <surname>Rao</surname>
              <given-names>A</given-names>
            </name>
            <name>
              <surname>Gupta</surname>
              <given-names>S</given-names>
            </name>
            <name>
              <surname>Dinda</surname>
              <given-names>AK</given-names>
            </name>
            <name>
              <surname>Sharma</surname>
              <given-names>A</given-names>
            </name>
            <name>
              <surname>Sharma</surname>
              <given-names>VK</given-names>
            </name>
            <name>
              <surname>Kumar</surname>
              <given-names>G</given-names>
            </name>
            <etal>et al</etal>
          </person-group>
          <article-title>Study of clinical, biochemical and immunological factors determining
stability of disease in patients with generalized vitiligo undergoing melanocyte
transplantation</article-title>
          <source>Br J Dermatol</source>
          <year>2012</year>
          <volume>166</volume>
          <fpage>1230</fpage>
          <lpage>1236</lpage>
          <pub-id pub-id-type="pmid">22329760</pub-id>
        </element-citation>
      </ref>
    </ref-list>
  </back>
</article>
</pmc-articleset>
